Table 2.
Schemes of delivered neoadjuvant treatments and related clinical response.
| Characteristics | All Patients | OPSII | MIBR | p-Value |
|---|---|---|---|---|
| 297 | 87 (29.3%) | 210 (70.7%) | ||
| Neoadjuvant chemotherapy - Anthracycline and/or taxanes - Anthracycline + taxanes - Other schemes |
5 (1.7%) 235 (79.1%) 57 (19.2%) |
0 (0%) 73 (83.9%) 14 (16.1%) |
5 (2.3%) 162 (77.2%) 43 (20.5%) |
0.385 |
| Regimens with trastuzumab | 98 (33%) | 24 (27.6%) | 74 (35.2%) | 0.096 |
| Clinical response on T - Clinical complete response - Clinical partial response - No response - Progression |
92 (30.9%) 189 (63.7%) 8 (2.7%) 8 (2.7%) |
23 (26.4%) 61 (70.1%) 2 (2.3%) 1 (1.1%) |
69 (32.9%) 128 (61%) 6 (2.9%) 7 (3.3%) |
0.425 |
| ycT - 0 - 1 - 2 - 3 |
92 (31%) 111 (37.4%) 79 (26.5%) 15 (5.1%) |
23 (26.4%) 37 (42.5%) 25 (28.7%) 2 (2.3%) |
69 (32.9%) 74 (35.2%) 54 (25.7%) 13 (6.2%) |
0.290 |
| Clinical Response on N - ycN0 - ycN+ |
231 (77.8%) 66 (22.2%) |
66 (75.9%) 21 (24.1%) |
165 (78.6%) 45 (21.4%) |
0.646 |